{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:43:27Z","timestamp":1776401007565,"version":"3.51.2"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006521","name":"STANFORD UNIVERSITY SCHOOL OF MEDICINE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008782","name":"Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008782","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.modpat.2023.100256","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T03:41:24Z","timestamp":1687923684000},"page":"100256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-3043","authenticated-orcid":false,"given":"Sheren","family":"Younes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia Palomino","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Libert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Johnsrud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robbie G.","family":"Majzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-1018","authenticated-orcid":false,"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2023.100256_bib1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/jcp.43.11.893","article-title":"Cellular expression of lymphocyte function associated antigens and the intercellular adhesion molecule-1 in normal tissue","volume":"43","author":"Smith","year":"1990","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.modpat.2023.100256_bib2","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1073\/pnas.79.23.7489","article-title":"Three distinct antigens associated with human T lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3","volume":"79","author":"Sanchez-Madrid","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.modpat.2023.100256_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4049\/jimmunol.147.1.14","article-title":"Interaction of CD2 with its ligand lymphocyte function-associated antigen-3 induces adenosine 3\u2032,5\u2032-cyclic monophosphate production in T lymphocytes","volume":"147","author":"Hahn","year":"1991","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.modpat.2023.100256_bib4","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.4049\/jimmunol.150.12.5338","article-title":"Anti-CD3-stimulated Ca2+ signal in individual human peripheral T cells. Activation correlates with a sustained increase in intracellular Ca2+","volume":"150","author":"Wacholtz","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.modpat.2023.100256_bib5","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1182\/blood.V89.10.3717","article-title":"CD2 rescues T cells from T-cell receptor\/CD3 apoptosis: a role for the Fas\/Fas-L system","volume":"89","author":"Ayroldi","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.modpat.2023.100256_bib6","article-title":"CD58 immunobiology at a glance","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol"},{"key":"10.1016\/j.modpat.2023.100256_bib7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1084\/jem.180.5.1665","article-title":"CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy","volume":"180","author":"Boussiotis","year":"1994","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"10.1016\/j.modpat.2023.100256_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41577-022-00738-9","article-title":"The CD58-CD2 axis in cancer immune evasion","volume":"22","author":"Quastel","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.modpat.2023.100256_bib9","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","author":"Esteban","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2023.100256_bib10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.2019001126","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","author":"Mottok","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.modpat.2023.100256_bib11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/gcc.22276","article-title":"Alterations of the CD58 gene in classical Hodgkin lymphoma","volume":"54","author":"Schneider","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2023.100256_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.modpat.2023.100256_bib13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"141","key":"10.1016\/j.modpat.2023.100256_bib14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.modpat.2023.100256_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2023.100256_bib16","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.modpat.2023.100256_bib17","author":"Majzner"},{"issue":"22","key":"10.1016\/j.modpat.2023.100256_bib18","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1182\/bloodadvances.2022007891","article-title":"CD58 loss in tumor cells confers functional impairment of CAR T cells","volume":"6","author":"Yan","year":"2022","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/j.modpat.2023.100256_bib19","article-title":"Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway","volume":"10","author":"Shen","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"10.1016\/j.modpat.2023.100256_bib20","article-title":"Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T-cell responses","volume":"132","author":"Romain","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.modpat.2023.100256_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2022","journal-title":"Cancer Cell"},{"issue":"suppl_1","key":"10.1016\/j.modpat.2023.100256_bib22","first-page":"D871","article-title":"The Stanford tissue microarray database","volume":"36","author":"Marinelli","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.modpat.2023.100256_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-60761-806-5_10","article-title":"Building \u201ctissue\u201d microarrays from suspension cells","volume":"644","author":"Zhao","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.modpat.2023.100256_bib24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.modpat.2023.100256_bib25","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J.\u00a0Clin. Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2023.100256_bib26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/j.modpat.2023.100256_bib27","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/eji.201646492","article-title":"CD2-CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection","volume":"46","author":"Rolle","year":"2016","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.modpat.2023.100256_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4049\/jimmunol.1401917","article-title":"CD58\/CD2 is the primary costimulatory pathway in human CD28-CD8+ T cells","volume":"195","author":"Leitner","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"10.1016\/j.modpat.2023.100256_bib29","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.4049\/jimmunol.144.12.4541","article-title":"Ligand binding to the LFA-3 cell adhesion molecule induces IL-1 production by human thymic epithelial cells","volume":"144","author":"Le","year":"1990","journal-title":"J\u00a0Immunol"},{"issue":"119","key":"10.1016\/j.modpat.2023.100256_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2020.01.006","article-title":"EZH2 inhibitors restore epigenetically silences CD58 expression in B-cell lymphomas","author":"Otsuka","year":"2020","journal-title":"Mol Immunol"},{"issue":"6","key":"10.1016\/j.modpat.2023.100256_bib31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.modpat.2023.100256_bib32","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat. Genet"},{"key":"10.1016\/j.modpat.2023.100256_bib33","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1158\/0008-5472.CAN-14-0643","article-title":"Molecular characterization of chronic-type adult T-cell leukemia\/lymphoma","volume":"74","author":"Yoshida","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.modpat.2023.100256_bib34","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.modpat.2023.100256_bib35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/gene.2016.30","article-title":"CD58 mutations are common in hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse","volume":"17","author":"Abdul Razak","year":"2016","journal-title":"Genes and Immunity"},{"key":"10.1016\/j.modpat.2023.100256_bib36","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2014.201","article-title":"The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing","volume":"28","author":"Liu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.modpat.2023.100256_bib37","doi-asserted-by":"crossref","first-page":"83294","DOI":"10.18632\/oncotarget.13065","article-title":"Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors","volume":"7","author":"Cao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.modpat.2023.100256_bib38","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1200\/JCO.2014.57.7080","article-title":"Diffuse large B-cell lymphoma classification system that associated normal B-cell subset phenotypes with prognosis","volume":"33","author":"Dybk\u00e6r","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2023.100256_bib39","first-page":"684","article-title":"The evolving use of CAR T-cell therapy in follicular lymphoma","volume":"19","author":"Nastoupil","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.modpat.2023.100256_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.modpat.2023.100256_bib41","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2023.100256_bib42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14656566.2021.2014815","article-title":"Tazemetostat: a treatment option for relapsed\/refractory follicular lymphoma","volume":"23","author":"Mondello","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.modpat.2023.100256_bib43","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/cas.15040","article-title":"Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan","volume":"112","author":"Izutsu","year":"2021","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.modpat.2023.100256_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-020-0274-9","article-title":"Anti-CD30 chimeric antigen receptor T cell therapy for relapsed\/refractory CD30+ lymphoma patients","volume":"10","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.modpat.2023.100256_bib45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2249.1992.tb05842.x","article-title":"Hodgkin's cells express a novel pattern of adhesion molecules","volume":"90","author":"Ellis","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.modpat.2023.100256_bib46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-642-83781-4_7","article-title":"The typical Reed-Sternberg phenotype and Ig gene rearrangement of Hodgkin's disease derived cell line ZO indicating a B-cell origin","volume":"117","author":"Poppema","year":"1989","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.modpat.2023.100256_bib47","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood.2020005546","article-title":"Rosetting T cells in hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58","volume":"136","author":"Veldman","year":"2020","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.modpat.2023.100256_bib48","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.modpat.2023.100256_bib49","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223001618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223001618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:24:38Z","timestamp":1760232278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395223001618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0893395223001618"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100256","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100256"}}